AbbVie obesity drug shows weight loss in early-stage trial
Tweet Send to a Friend
AbbVie Inc. (NYSE: ABBV) reported that its experimental obesity treatment ABBV-295 demonstrated weight reduction of up to 9.79% in a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
